Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) is expected to announce its results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.0070) per share and revenue of $0.42 million for the quarter.
Spectral Diagnostics Stock Up 7.5%
OTCMKTS EDTXF opened at $0.71 on Thursday. The firm’s 50 day moving average is $0.82 and its 200-day moving average is $0.94. The company has a market capitalization of $208.19 million, a PE ratio of -7.07 and a beta of 0.21. Spectral Diagnostics has a 12-month low of $0.64 and a 12-month high of $1.10.
Spectral Diagnostics Company Profile
Spectral Diagnostics Inc is a Canadian medical technology company focused on improving the diagnosis and treatment of sepsis and septic shock. The company develops products designed to identify endotoxin activity, an important factor in certain severe infections and inflammatory conditions.
Its principal diagnostic product is the Endotoxin Activity Assay, a blood test intended to measure a patient’s level of endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Featured Stories
- Five stocks we like better than Spectral Diagnostics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
